CHROMAgar Candida with fluconazole: Comparison with microdilution techniques;CHROMAgar Candida más fluconazol: Comparación con técnicas de microdilución

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 21, Issue 9, 2003, Pages 493-497

  Linares, María José ^a,b   Charriel, Guadalupe ^a   Solís, Francisco ^a   Casal, Manuel ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Universidad de Cordoba   (Spain)

Author keywords

CHROMAgar Candida with fluconazole; Fluconazole; Yeasts

Indexed keywords

FLUCONAZOLE;

ACCURACY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LAMBICA; CANDIDA PARAPSILOSIS; CANDIDA PELLICULOSA; CANDIDA TROPICALIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DATA ANALYSIS; DILUTION; DRUG SENSITIVITY; EVALUATION; FUNGAL STRAIN; FUNGUS ISOLATION; NONHUMAN; SACCHAROMYCES CEREVISIAE; SCREENING; TECHNIQUE; YEAST;

EID: 0345303704     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13052333     Document Type: Article

References (23)

1. Viudes C, Cantón E, Pemán J, López-Ribot JL, Gobernado M. Correlación entre las pruebas de sensibilidad in vitro a los antifúngicos y la evolución clínica de los pacientes con candidiasis y criptococosis. Rev Esp Quimioterap 2002;15:32-42.
2. Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis 1996;22:S112-8.
3. Patterson TF, Kirkpatrick WR, Revankar SG, McAtee RK, Fothergill AW, Mc Carthy DI, et al. Comparative evaluation of macrodilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicans. J Clin Microbiol 1996;34:3237-9.
4. Bouchara JP, Declerck P, Cimon B, Planchenault C, De Gentile L, Chabasse D. Routine use of CHROMAgar Candida medium for presumptive identification of Candida yeast species and detection of mixed fungal populations. Clin Microbiol Infect 1996;2:202-8.
5. a ed. Bilbao: Rev Iberoam Micol, 2001; p. 11-1 a 11-18.
6. Odds FC, Bernaerts R. CHROMAgar Candida, a new differential isolation medium for presumptive identification of clinically important Candida spp. J Clin Microbiol 1994;32:1923-9.
7. Casal M, Linares MJ, Solís F, Rodríguez FC. Appearance of colonies of Prototheca on CHROMAgar Candida medium. Mycopathol 1997;137:79-82.
8. Marco F, Pfaller MA, Messer S, Jones RN. In vitro activities of voriconazole (UK-109.4496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother 1998;42:161-3.
9. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts M27-A. Villanova, 1997.
10. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghaunoum MA, et al. Antifungal susceptibility testing: Practical aspects and current challenges. Clin Microbiol Reviews 2001;14:643-58.
11. Espinel-Ingroff A, Warnock DW, Vázquez JA, Arthington-Skaggs BA. In vitro antifungal susceptibility methods and clinical implications of antifungal resistance. Med Mycol 2000;38:293-304.
12. Espinel-Ingroff A, Rodríguez-Tudela JL, Martínez-Suá rez JV. Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards Reference Macrodilution Method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans. J Clin Microbiol 1995;33:3154-8.
13. Patterson TF, Revankar SG, Kirkpatrick WR, Dib O, Fothergill AW, Redding SW, et al. Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J Clin Microbiol 1996;34:1794-7.
14. Espinel-Ingroff A, Kish CW Jr, Kerkering TM, Fromtling RA, Bartizal K, Galgiani JN, et al. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 1992;30:3138-45.
15. Espinel-Ingroff A, Pfaller M, Messer SA, Knapp CC, Killian S, Norris HA, et al. Multicenter comparison off the Sensititre® YeastOne colorimetric antifungal panel with the National Committee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococus spp. and other yeast-like organisms. J Clin Microbiol 1999;37:591-5.
16. Powell HL, Sand CA, Rennie RP. Evaluation of CHROMAgar Candida for presumptive identification of clinically important Candida spp. Diagn Microbiol Infect Dis 1998;32:201-4.
17. Willinger B, Manafi M. Evaluation of CHROMAgar Candida for rapid screening of clinical specimens for Candida spp. Mycoses 1999;42:61-5.
18. Verghese SL, Padmaja P, Sutha P, Mathew T, Soma J. Rapid identification of fluconazole resistance using CHROMAgar Candida. Indian J Pathol Microbiol 2000;43:343-6.
19. Fromtlig RA, Galgiani JN, Pfaller MA, Espinel-Ingroff A, Bartizal KF, Bartlett MS, et al. Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother 1993;37:39-45.
20. Pfaller MA, Rinaldi MG, Galgiani JN, Bartlett MS, Body BA, Espinel-Ingroff A, et al. Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother 1990;34:1648-54.
21. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole resistant Candida in patients with AIDS: Prevalence and microbiology. Clin Infect Dis 1997;24:28-34.
22. Canle D, Velasco D, Tomás M, Molina F, Villanueva R, Durán MT. Cribado de Candida spp. con sensibilidad disminuida a fluconazol mediante CHROMAgar Candida con fluconazol. Enferm Infecc Microbiol Clin 2002;20(Suppl 1):164.
23. Jianping X, Vilgalys R, Mitchell TG. Colony size can be used to determine the MIC of fluconazole for pathogenic yeasts. J Clin Microbiol 1998;36:2383-5.